Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam
Launched by NOVO NORDISK A/S · Feb 20, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- • Male or female aged 18 years or older at the time of signing informed consent.
- • Presence of at least one Weight-related complication.
- Exclusion Criteria:
- • Participants less than 18 years of age at the time of signing informed consent.
- • Pregnant women and individuals with recent weight loss due to illness, defined as more than 5 percent (%) weight loss in the past 6 months.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangalore, Karnataka, India
Karachi, , Pakistan
Kolkata, West Bengal, India
Ansari Nagar, New Delhi, India
Belgaum, Karnataka, India
Mumbai, Maharashtra, India
New Delhi, Delhi, India
Lahore, , Pakistan
Metro Manila, San Juan, Philippines
Ho Chi Minh, Tan Binh, Vietnam
Bhubaneswar, Odisha, India
Islamabad, , Pakistan
Lahore, , Pakistan
Multan, , Pakistan
Peshawar, , Pakistan
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported